When a patient is diagnosed with a bacterial infection, medical staff need to identify the species attacking the body before it can be treated. The problem is, this process can take a few days and may ...

Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering. The collaborations are geared to enable the integration of two novel conjugation ...

Lonza officials say the company has strengthened its advanced synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other ...

Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates. Lonza and Singzyme, a biotechnology company specializing in developing enzymes for protein ...

The market for HPAPIs is growing rapidly with the research industry's emphasis on oncology. The market is growing rapidly—probably the most aggressive growth rate that we see in the pharmaceutical ...

A technique developed by Miami University associate professors of chemistry and biochemistry Dominik Konkolewicz and Rick Page may help enable more rapid and efficient development of new materials for ...

Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes. A new, easy-to-adapt and ...

This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will ...

Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated ...